Related Experiment Video
Updated: May 28, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Rotavirus vaccine and health care utilization for diarrhea in U.S. children
Jennifer E Cortes1, Aaron T Curns, Jacqueline E Tate
1Epidemic Intelligence Service, Office of Workforce and Career Development, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Insights
Routine rotavirus vaccination (RV5) significantly reduced diarrhea-related healthcare use and costs in U.S. children. The vaccine led to substantial decreases in hospitalizations and emergency visits, saving millions in treatment costs.
Area of Science:
- Public Health
- Vaccinology
- Pediatric Gastroenterology
Background:
- Pentavalent rotavirus vaccine (RV5) was introduced for routine U.S. infant vaccination in 2006.
- Monitoring vaccine impact on healthcare utilization is crucial for public health policy.
Purpose of the Study:
- To assess the impact of rotavirus vaccine (RV5) on diarrhea-associated healthcare utilization and costs in U.S. children.
- To estimate indirect benefits of RV5 vaccination in unvaccinated children.
Main Methods:
- Utilized MarketScan databases to analyze RV5 coverage and diarrhea-related healthcare use from 2001-2009 in children under 5.
- Compared healthcare use rates in vaccinated and unvaccinated children during rotavirus season.
- Extrapolated national reductions in hospitalizations and associated costs.
Main Results:
- By late 2008, RV5 coverage reached 73% in infants and 64% in 1-year-olds.
- Diarrhea hospitalizations decreased by 33% in 2007-2008 and 25% in 2008-2009 post-vaccine introduction.
- Rotavirus-specific hospitalizations saw reductions of 75% and 60% in the respective periods.
- Significant reductions were observed in emergency department and outpatient visits for diarrhea.
- Nationally, an estimated 64,855 hospitalizations were averted, saving approximately $278 million between 2007-2009.
Conclusions:
- The introduction of rotavirus vaccine has led to substantial decreases in diarrhea-associated healthcare utilization and medical expenditures among U.S. children.
- RV5 vaccination demonstrates significant public health benefits through reduced disease burden and healthcare costs.
Background:
Routine vaccination of U.S. infants with pentavalent rotavirus vaccine (RV5) began in 2006.
Methods:
Using MarketScan databases, we assessed RV5 coverage and diarrhea-associated health care use from July 2007 through June 2009 versus July 2001 through June 2006 in children under 5 years of age. We compared the rates of diarrhea-associated health care use in unvaccinated children in the period from January through June (when rotavirus is most prevalent) in 2008 and 2009 with the prevaccine rates to estimate indirect benefits. We estimated national reductions in the number of hospitalizations for diarrhea, and associated costs, by extrapolation.
Results:
By December 31, 2008, at least one dose of RV5 had been administered in 73% of children under 1 year of age, 64% of children 1 year of age, and 8% of children 2 to 4 years of age. Among children under 5 years of age, rates of hospitalization for diarrhea in 2001-2006, 2007-2008, and 2008-2009 were 52, 35, and 39 cases per 10,000 person-years, respectively, for relative reductions from 2001-2006 by 33% (95% confidence interval [CI], 31 to 35) in 2007-2008 and by 25% (95% CI, 23 to 27) in 2008-2009; rates of hospitalization specifically coded for rotavirus infection were 14, 4, and 6 cases per 10,000 person-years, respectively, for relative reductions in the rate from 2001-2006 by 75% (95% CI, 72 to 77) in 2007-2008 and by 60% (95% CI, 58 to 63) in 2008-2009. In the January-June periods of 2008 and 2009, the respective relative rate reductions among vaccinated children as compared with unvaccinated children were as follows: hospitalization for diarrhea, 44% (95% CI, 33 to 53) and 58% (95% CI, 52 to 64); rotavirus-coded hospitalization, 89% (95% CI, 79 to 94) and 89% (95% CI, 84 to 93); emergency department visits for diarrhea, 37% (95% CI, 31 to 43) and 48% (95% CI, 44 to 51); and outpatient visits for diarrhea, 9% (95% CI, 6 to 11) and 12% (95% CI, 10 to 15). Indirect benefits (in unvaccinated children) were seen in 2007-2008 but not in 2008-2009. Nationally, for the 2007-2009 period, there was an estimated reduction of 64,855 hospitalizations, saving approximately $278 million in treatment costs.
Conclusions:
Since the introduction of rotavirus vaccine, diarrhea-associated health care utilization and medical expenditures for U.S. children have decreased substantially.
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Bacterial Gastroenteritis
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Cholera
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

